A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of Intravenous QAX576.
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2010
At a glance
- Drugs Dectrekumab (Primary)
- Indications Allergic rhinitis; Asthma; Oesophagitis
- Focus Adverse reactions
- 28 Nov 2007 Status changed from recruiting to completed.
- 03 Feb 2007 New trial record.